MedPath

Ginkgo biloba

Generic Name
Ginkgo biloba
Drug Type
Biotech
CAS Number
90045-36-6
Unique Ingredient Identifier
19FUJ2C58T
Background

Ginkgo biloba extract contains a group of terpene lactones (notably, ginkgolides and diterpenes) and ginkgo flavone glycosides (notably, ginkgetin, bilobetin, and sciadopitysin) that have antioxidant and vasoactive properties. Most of the studies that investigate the effect of ginkgo biloba use the standardized extract of Ginkgo biloba (EGb) 761 (EGb761), which was developed by a German pharmaceutical company in 1964. EGb761 contains 6% terpene lactones and 24% flavonoid glycosides. Flavonoids include quercetin, rutin, kaempferol, and isorhamnetin. Lactones include ginkgolide A, ginkgolide B, ginkgolide C, bilobalide, and ginkgotoxin, a lactone that is structurally related to pyridoxine. Ginkgo biloba is an herbal plant that is now cultivated worldwide. It is originally native to China, and ginkgo biloba extract has been used in traditional Chinese medicine for centuries.

After its nootropic properties were discovered, ginkgo biloba has gained attention as a therapeutic ingredient for memory and concentration enhancement in cognitive impairment and neurogenerative diseases, such as dementia. Ginkgo biloba was investigated in preliminary studies for a variety of therapeutic purposes such as improving cardiovascular health, sexual dysfunction, psychiatric disorders, skin disorders, and glaucoma. Ginkgo biloba is found in a number of homeopathic and over-the-counter herbal products and dietary supplements, but it has no approved therapeutic indications by regulatory bodies, such as the FDA, EMA, and Health Canada. Ginkgo folium, the leaf extract of Ginkgo biloba, is considered an anti-dementia drug by the World Health Organization.

Indication

Ginkgo biloba does not currently have any approved therapeutic indications, and there is insufficient evidence to support its unapproved use. It is available in over-the-counter herbal products mostly for oral use, to improve memory and cognitive problems.

Associated Conditions
Cognitive Dysfunctions, Cognitive Functioning, Depression

Effect of Ginkgo Biloba Special Extract LI 1370 on Dual-tasking in Patients With MCI

Phase 4
Completed
Conditions
Mild Cognitive Impairment
Interventions
First Posted Date
2010-01-11
Last Posted Date
2015-10-14
Lead Sponsor
University Hospital, Basel, Switzerland
Target Recruit Count
50
Registration Number
NCT01046292
Locations
🇨🇭

Basel University Hospital, Basel Mobility Center, Basel, Basel-Stadt, Switzerland

Study Effects of Ginkgo Biloba Extract on Endothelial Cell Function and Genetic Effects on the Response to Ginkgo Biloba Extract in Diabetic Patients With Stable Coronary Artery Disease

Phase 4
Conditions
Type 2 Diabetes Mellitus
Coronary Artery Disease
First Posted Date
2009-12-23
Last Posted Date
2009-12-23
Lead Sponsor
Taipei Veterans General Hospital, Taiwan
Target Recruit Count
60
Registration Number
NCT01038050
Locations
🇨🇳

Taipei Veterans General Hospital, Taipei, Taiwan

Trial of Ginkgo as a Treatment for Cognitive Problems in Multiple Sclerosis

Phase 2
Completed
Conditions
Multiple Sclerosis
Cognitive Ability, General
Interventions
Drug: Placebo
First Posted Date
2009-02-11
Last Posted Date
2014-06-06
Lead Sponsor
US Department of Veterans Affairs
Target Recruit Count
120
Registration Number
NCT00841321
Locations
🇺🇸

Portland VA Medical Center, Portland, OR, Portland, Oregon, United States

🇺🇸

VA Puget Sound Health Care System, Seattle, Seattle, Washington, United States

Efficacy and Safety of Ginkgo Biloba Extract in Mild Cognitive Impairment and Cerebrovascular Insufficiency

Phase 4
Completed
Conditions
Mild Cognitive Impairment
Cerebrovascular Insufficiency
Interventions
First Posted Date
2007-03-13
Last Posted Date
2015-09-28
Lead Sponsor
Milsing d.o.o.
Target Recruit Count
90
Registration Number
NCT00446485
Locations
🇭🇷

University Department of Neurology, Sestre milosrdnice University Hospital, Vinogradska 29, Zagreb, Croatia

Efficacy and Tolerability of Ginkgo Biloba Extract in Patients With Raynaud´s Phenomenon

Phase 2
Completed
Conditions
Raynaud Disease
Interventions
First Posted Date
2005-11-09
Last Posted Date
2017-05-22
Lead Sponsor
VSM Geneesmiddelen b.v.
Target Recruit Count
41
Registration Number
NCT00251238
Locations
🇳🇱

UMC ST Radboud, Nijmegen, Gelderland, Netherlands

Ginkgo Biloba to Improve Short-Term Memory Losses Associated With Electroconvulsive Therapy (ECT)

Phase 1
Terminated
Conditions
Memory, Short-Term
Interventions
Other: matched placebo
First Posted Date
2003-10-13
Last Posted Date
2018-07-18
Lead Sponsor
Medical University of South Carolina
Target Recruit Count
50
Registration Number
NCT00070954
Locations
🇺🇸

UMDNJ - NJ Medical School, Newark, New Jersey, United States

EGb761 in Maintaining Mental Clarity in Women Receiving Chemotherapy for Newly Diagnosed Breast Cancer

Phase 3
Completed
Conditions
Breast Cancer
Neurotoxicity
Interventions
Other: Placebo
First Posted Date
2003-01-27
Last Posted Date
2016-07-06
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
226
Registration Number
NCT00046891
Locations
🇺🇸

Graham Hospital, Canton, Illinois, United States

🇺🇸

St. John Macomb Hospital, Warren, Michigan, United States

🇺🇸

Hurley Medical Center, Flint, Michigan, United States

and more 167 locations

Effect of Ginkgo Biloba on Phenytoin Elimination

Phase 1
Completed
Conditions
Healthy
First Posted Date
2002-12-10
Last Posted Date
2008-03-04
Lead Sponsor
National Institutes of Health Clinical Center (CC)
Target Recruit Count
12
Registration Number
NCT00011063
Locations
🇺🇸

Warren G. Magnuson Clinical Center (CC), Bethesda, Maryland, United States

Treatment for Early Memory Loss

Phase 4
Completed
Conditions
Cognition Disorders
Alzheimer Disease
First Posted Date
2002-07-26
Last Posted Date
2014-03-03
Lead Sponsor
University of Iowa
Target Recruit Count
40
Registration Number
NCT00042172
Locations
🇺🇸

University of Iowa Department of Psychiatry, Iowa City, Iowa, United States

Ginkgo Biloba: Antidepressant-Induced Sexual Dysfunction

Phase 2
Completed
Conditions
Hypoactive Sexual Desire Disorder
Sexual Dysfunctions, Psychological
First Posted Date
2002-04-22
Last Posted Date
2006-08-18
Lead Sponsor
National Center for Complementary and Integrative Health (NCCIH)
Registration Number
NCT00034021
Locations
🇺🇸

University of Texas, Austin, Austin, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath